Physician profile
Michael E Daun
NPI 1457353708
$2,200.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $201 · 2021: $536 · 2022: $270 · 2023: $465 · 2024: $39.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $546.83 | 2019-2024 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $500.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $280.52 | 2019-2020 | |
| Allergan, INC. | $272.02 | 2019-2021 | |
| Abbvie INC. | $176.37 | 2022-2023 | Durysta, Ozurdex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.84 | 2019 | |
| Eyepoint US, INC. | $59.82 | 2020-2021 | |
| Biogen, INC. | $58.16 | 2022 | |
| Apellis Pharmaceuticals, INC. | $57.73 | 2022-2023 | Syfovre |
| Astellas Pharma US INC | $53.30 | 2023 | |
| Genentech USA, INC. | $50.24 | 2021-2023 | Vabysmo |
| Ocular Therapeutix, INC. | $18.10 | 2020 | |
| Bausch & Lomb Americas INC. | $16.58 | 2023 | Xipere, Retisert, Visudyne |
| Spark Therapeutics, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.